Expression of CD45 in non-hematopoietic cells: implications in regenerative medicine and disease management.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2024-01-01 Epub Date: 2024-07-26 DOI:10.1080/17460751.2024.2378627

Madhurima Das, Prajakta Teli, Anuradha Vaidya, Vaijayanti Kale

引用次数: 0

Abstract

CD45 plays a crucial role in the regulation of hematopoiesis. However, a comprehensive understanding of its role in non-hematopoietic cells is lacking. Several tissue precursors express CD45, indicating its crucial role in tissue regeneration. These precursors would fall prey to the recent therapies involving CD45 as a target. CD45⁺ double-positive tumor cells contribute to cancer progression, but whether CD45 is involved in the process needs to be investigated. Recently, we showed that aging induces CD45 expression in mesenchymal stromal cells and affects their differentiation potential. In this review, we, for the first time, unravel the important implications of the expression of CD45 in non-hematopoietic cells and provide novel insights into its potential therapeutic target in regenerative medicine and disease management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非造血细胞中 CD45 的表达：对再生医学和疾病管理的影响。

CD45 在调节造血过程中发挥着至关重要的作用。然而，人们对其在非造血细胞中的作用还缺乏全面的了解。一些组织前体表达 CD45，表明它在组织再生中起着关键作用。这些前体细胞会成为最近以 CD45 为靶点的疗法的牺牲品。CD45+ 双阳性肿瘤细胞有助于癌症进展，但 CD45 是否参与了这一过程还有待研究。最近，我们发现衰老会诱导间充质基质细胞中 CD45 的表达，并影响其分化潜能。在这篇综述中，我们首次揭示了 CD45 在非造血细胞中表达的重要意义，并对其在再生医学和疾病治疗中的潜在治疗靶点提供了新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

期刊最新文献

Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction. Industry updates from the field of stem cell research and regenerative medicine in August 2024.